As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023

99,644

Complementary compensation Shares

440,000

Awarded shares

970,000

Imposed fine

$ 16,214

COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 21, 2023	Jun. 26, 2022	Jul. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Description for advisory agreement			As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023
Stock based compensation				$ 109,636	$ 109,636	$ 326,525	$ 214,505
Payment of additional tax						99,644
Additional stock consideration						$ 264,000
Complementary compensation Shares						440,000
Four Third Party Consultants [Member]
Awarded shares	970,000
Awarded share value	$ 999,100
Phase 1 [Member]
Project cost		$ 838,450
Phase 2 [Member]
Project cost		$ 907,084
National Medicines Agency [Member] \| General And Administrative Expense [Member]
Stock based compensation				$ 264,750	$ 0	$ 728,250	$ 0	$ 77,250
Imposed fine						$ 16,214